09:07 AM EDT, 06/24/2025 (MT Newswires) -- PharmaTher Holdings ( PHRRF ) on Tuesday said it has been granted a U.S. patent that covers the use of ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS).

This patent, which expires in 2041, complements PharmaTher's ( PHRRF ) existing Orphan Drug Designation for ketamine, which grants seven years of market exclusivity in the U.S. following drug approval, PharmaTher ( PHRRF ) added.

"The grant of this U.S. patent is a monumental achievement for PharmaTher ( PHRRF ) and a critical step in solidifying our leadership position in developing novel ketamine therapies for severe neurological disorders," said Chief Executive Fabio Chianelli. "Combined with our Orphan Drug Designation, we have built a formidable moat around our ketamine program for ALS. This dual protection of intellectual property and regulatory exclusivity is a cornerstone of our strategy to unlock significant shareholder value as we advance towards clinical development and potential commercialization for a patient population with an urgent unmet medical need."